Halogenated alkane volatile general anesthetic

Plain-language summaryIntrigue 50 / 100

Halothane was the first clinically successful non-flammable halogenated volatile anesthetic, synthesized at ICI in 1951 and dominant from 1956 through the 1980s. It displaced the dangerous flammable agents (diethyl ether, chloroform) that preceded it. The blood-gas partition coefficient of 2.4 is slow by modern standards, and the mechanism is the standard volatile anesthetic profile (GABA-A, K2P, glycine, NMDA). Two issues drove its retirement: halothane hepatitis, an immune-mediated necrosis tied to trifluoroacetyl protein adducts generated by 20 percent hepatic metabolism (incidence around 1 in 35,000), and a cardiovascular profile featuring myocardial depression and sensitization to catecholamine arrhythmias. Still the dominant inhalational anesthetic in lower-resource settings owing to acquisition cost (about a third of isoflurane). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

23/100

Historically dominant volatile anesthetic, decisively superseded by safer ether agents, minimal research value today

Honestly, theres not a lot to say here that isn’t already obvious from the history. Halothane was genuinely important once: Charles Suckling’s 1951 synthesis at ICI and Michael Johnstone’s 1956 clinical introduction gave anesthesia its first non-flammable volatile, replacing the terrifying fire risk of diethyl ether and the frank toxicity of chloroform. For roughly three decades it was the dominant inhalational agent across most of the world. That legacy is real. It doesn’t translate into research interest in 2026.

The problem starts with mechanism. Halothane’s action is the canonical volatile anesthetic profile: GABA-A potentiation, K2P channel activation, glycine receptor modulation, partial NMDA inhibition. This is shared, in essentially the same proportions, by isoflurane, sevoflurane, desflurane, and every other modern volatile. There’s nothing mechanistically distinctive about halothane relative to its successors; if anything, the catecholamine sensitization and incomplete NMDA component are outright liabilities. You can’t use halothane to probe a question that a modern agent couldn’t answer more cleanly and safely.

The displacement from clinical practice was driven by two decisive findings. First, halothane hepatitis: immune-mediated hepatic necrosis at roughly 1 in 35,000 exposures, attributed to CYP2E1-mediated oxidation generating trifluoroacetyl protein adducts that function as neoantigens. This mechanism is well understood and well replicated across independent groups. The adduct chemistry is actually the most interesting thing about halothane from a research perspective, and it remains a usable model system for studying CYP2E1-mediated haptenation and drug-induced liver injury (DILI) immunology. Second, the cardiovascular profile: dose-dependent myocardial depression, catecholamine sensitization creating genuine arrhythmia risk with epinephrine co-administration, and a blood-gas partition coefficient of 2.4 compared to 0.42 for desflurane, which makes induction and emergence sluggish by any modern standard.

Where halothane still appears is resource-limited settings. Acquisition cost runs roughly one-third of isoflurane, and it doesn’t require the specialized heated vaporizer infrastructure that desflurane demands. Pediatric induction historically favored its non-pungent character, but sevoflurane has displaced it for that indication wherever budget allows. Veterinary use persists in some jurisdictions. None of these represent a forward research angle worth pursuing from a bench perspective.

We think the only legitimate research use case today is as a reference compound in CYP2E1 hepatotoxicity or DILI mechanistic work, where the trifluoroacetyl adduct chemistry is well-characterized enough to serve as a positive control. That’s genuinely narrow. A serious investigator wouldn’t anchor a research program to halothane in 2026 unless the specific question was the adduct biology itself, and even then, the hepatotoxicity literature on this mechanism has been fairly well mined. The evidence base is solid and the mechanism is thoroughly understood. Those are compliments that translate to a low score here.

Novelty: 8
Mechanism promise: 12
In-category differentiation: 10
Evidence quality: 72
Translational signal: 25
Research bench value: 28

Rationale Halothane scores low across novelty, mechanism, and differentiation because it shares the generic volatile anesthetic mechanism with all successor agents and has been decisively displaced on every meaningful clinical dimension; the only residual bench angle is as a CYP2E1/DILI model compound via the trifluoroacetyl adduct chemistry, which is real but narrow. Evidence quality pulls the overall up modestly owing to decades of well-characterized clinical data, but not enough to move the needle on a compound this thoroughly superseded.

Halogenated alkane volatile general anesthetic

The first clinically successful non-flammable halogenated volatile anesthetic, dominant from 1956 through the 1980s, displaced by ether-class agents owing to halothane hepatitis.

Abstract

Halothane (2-bromo-2-chloro-1,1,1-trifluoroethane; CAS 151-67-7; molecular formula C2HBrClF3; molecular weight 197.38) is a halogenated alkane volatile anesthetic synthesized by Charles Suckling at ICI in 1951 and introduced clinically by Michael Johnstone in 1956. Halothane was the first non-flammable volatile to displace diethyl ether and chloroform as the dominant inhalational agent and remained in widespread use through the 1980s before isoflurane and the newer ethers superseded it. The minimum alveolar concentration (MAC) at age 40 is 0.75 percent in oxygen; the blood-gas partition coefficient is 2.4, slower than the modern ether agents. Mechanism is the standard volatile profile (GABA-A potentiation, K2P channel activation, glycine and NMDA modulation). Cardiovascular effects include dose-dependent myocardial depression with preserved or modestly reduced systemic vascular resistance, sensitization to catecholamine-induced arrhythmias (a clinically important interaction with epinephrine), and bradyarrhythmia. The principal limitations that drove displacement are halothane hepatitis (immune-mediated hepatic necrosis with an incidence of approximately 1 in 35,000 cases, attributed to trifluoroacetyl protein adducts generated by 20 percent hepatic metabolism through CYP2E1), and the negative inotropic and arrhythmogenic profile relative to the ether agents. Halothane remains the dominant inhalational anesthetic in lower-resource settings owing to acquisition cost (manufacturer-stated cost approximately one-third of isoflurane). Veterinary use persists in some jurisdictions. The global warming potential is moderate (GWP100 approximately 50). Pediatric induction was a historical strength owing to the non-pungent character; sevoflurane has displaced halothane for this indication in most jurisdictions.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1304Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Halogenated alkane volatile general anesthetic

Halothane

Abstract

Read the full monograph